arrow
M

Miguel-Ángel Berciano-Guerrero

hospital regional universitario
H指数:10
被引数:444

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

标题:西班牙免疫治疗和靶向治疗时代未知原发灶黑色素瘤的特征:前瞻性真实世界研究GEM 1801的结果

2025-12-200
PRE
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

西班牙晚期黏膜黑色素瘤患者的治疗效果:来自真实世界GEM1801研究的结果

2025-12-010
PRE
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

应答率和长期生存率在晚期黑色素瘤患者中的表现:来自前瞻性队列研究gem-1801的数据

2025-11-280
OAAI
Randomized, Double-Blind, Phase III LEAP-003 Study of First-Line Lenvatinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab for Unresectable or Metastatic Melanoma

随机、双盲、III期LEAP-003研究:比较一线仑伐替尼联合帕博利珠单抗与安慰剂联合帕博利珠单抗治疗不可切除或转移性黑色素瘤的疗效。

2025-08-280
PREAI
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

肢端黑色素瘤患者中基于抗PD-1抗体免疫疗法的效果不佳:西班牙黑色素瘤组(GEM)登记研究的结果

2025-08-210
PRE
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801)

复发治疗和再挑战使用BRAF/MEK抑制剂在转移性黑色素瘤患者中的效果:来自西班牙黑色素瘤登记系统(GEM-1801)的真实世界结果

2025-07-270
PRE
Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study

Cosibelimab在晚期皮肤鳞状细胞癌(CSCC)中的长期疗效和安全性结果:关键性研究

2024-09-010
PRE
Oncogene-addicted solid tumors and microbiome-lung cancer as a main character: a narrative review
2024-08-010
OAAI
Encorafenib and binimetinib followed by radiotherapy for patients with BRAFV600-mutant melanoma and brain metastases (E-BRAIN/GEM1802 phase II study)

恩科非尼和比尼美替尼联合放疗治疗BRAFV600-mutant黑色素瘤和脑转移患者 (e-brain/GEM1802 II期研究)

2024-07-010
OAAI
Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
2023-10-010
PRE
Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study
2022-09-010
PRE
Elderly patients (pts) with advanced melanoma: Results from the prospective real-world study GEM1801
2022-09-010
OAAI
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
2021-12-0129
OAAI